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 The enzyme PCSK9 binds to the hepatic
LDL receptor and targets it for a
intracellular degradation, leading to
decreased number of LDL receptor on
cells and reduced removal of circulating
LDL cholesterol.
 The usefulness of circulating PCSK9 as a
marker for risk of coronary heart disease in
the general population remains unclear.
 In this large prospective population
study, serum levels of PCSK9 were
modestly associated with increased risk of
myocardial infarction in age- and sex-
adjusted analysis. However, after adjust-
ment for LDL-C and other lipids, the
strength of the association was largely
attenuated.
 Our ﬁndings suggest that serum levels of
PCSK9 do not contribute additional useful
information in cardiovascular risk
assessment beyond the information
provided by lipid measurements.
 Moreover, our results are consistent with
the biological understanding of PCSK9
and of its effect on atherosclerosis being
mainly mediated by changes in LDL-
receptor function.nce and Technology, Trondheim,
Endocrinology, St. Olavs Hospital,
, Sweden; eDepartment of Internal
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AB BAND ACRONYM S
BMI = body mass index
CI = conﬁdence interval
CRP = C-reactive protein
CVD = cardiovascular disease
HDL-C = high-density
lipoprotein cholesterol
hsCRP = high-sensitivity
C-reactive protein
LDL = low-density lipoprotein
LDL-C = LDL cholesterol
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MaThe usefulness of circulating proprotein convertase subtilisin-kexin type 9 (PCSK9) as a risk marker of coronary
heart disease in the general population remains unclear. In a nested case-control study in Norway, 1,488
incident myocardial infarctions were registered during 11.3 years of follow-up and compared with 3,819 con-
trols. Compared with participants in the lowest quartile of PCSK9, myocardial infarction risk was 47% higher in
the highest quartile after adjustment for age and sex. After additional adjustment for low-density lipoprotein
cholesterol, the association was strongly attenuated. Thus, circulating PCSK9 does not contribute useful in-
formation in the assessment of myocardial infarction risk in the general population beyond the information
provided by lipid measurements. (J Am Coll Cardiol Basic Trans Science 2016;1:568–75) © 2016 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).myocardial infarctionMI =OR = odds ratio
PCSK9 = proprotein
convertase subtilisin-kexin
type 9T he enzyme proprotein convertase subtilisin-kexin type 9 (PCSK9) binds to the hepaticlow-density lipoprotein (LDL) receptor and
targets it for intracellular degradation, leading to
decreased number of LDL receptor on cells and
reduced removal of circulating LDL cholesterol
(LDL-C) (1). The importance of PCSK9 for LDL-C ho-
meostasis is illustrated in individuals with loss- and
gain-of-function mutations in this enzyme, leading
to hypo- or hypercholesterolemia, respectively, with
dramatic effects on the incidence of atherosclerotic
cardiovascular disease (CVD) (2). Anti-PCSK9 thera-
pies have recently been approved for clinical use
and seem to reduce LDL-C levels and to lower inci-
dence of CVD in patients with hyperlipidemia. The ef-
fect of the medication is currently under
investigation in other high-risk populations (1,3,4).
Results of recent studies suggest that circulating
PCSK9 is positively associated with established risk
factors for CVD, including LDL-C, triglycerides,
glucose, prevalent diabetes, body mass index (BMI),
carotid intima media thickness, and C-reactive pro-
tein (CRP) (5–7) as well as common and low-frequency
genetic variants in the PCSK9 locus (8). Furthermore,
high PCSK9 levels predict adverse outcomes in
patients with established CVD (9,10). To this end,
however, only a few studies have examinedchnology, Trondheim, Norway; iDepartment of Infectious Diseases, St. Ola
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general population, and results have been
conﬂicting. Thus, Leander et al. (11) found a
dose-dependent association between PCSK9 and
incident events of CVD (n ¼ 491) in the general popu-
lation (n ¼ 4,232). By contrast, Ridker et al. (12) found
no association between PCSK9 and risk of cardiovas-
cular events in a nested case-control study from the
Women’s Health Study (n ¼ 358 in each group), and
Zhu et al. (13) found no association in a follow-up of
1,527 middle-aged men.
Although PCSK9 appears to play a crucial role in
atherosclerosis, the usefulness of circulating PCSK9
as a biomarker for risk of CVD in the general popula-
tion remains unclear. Therefore, we conducted a
nested case-control study within the general popu-
lation in Norway (HUNT [Nord-Trøndelag Health]
study), and assessed serum levels of PCSK9 in rela-
tion to risk of myocardial infarction (MI) among 1,488
patients with a ﬁrst incident MI and 3,819 age- and
sex-matched controls.
METHODS
STUDY POPULATION. The HUNT Study constitutes a
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570of the population in Nord-Trøndelag County in
Norway. Nord-Trøndelag is 1 of 19 Norwegian counties
and is located in the central part of Norway. The pop-
ulation is stable and ethnically homogenous, with only
a small percentage (3%) of people of non-Caucasian
origin. The size of the population was stable between
the HUNT surveys, with a net emigration out of the
county of only 0.3% per year (14).
We conducted a case-control study nested within
the second wave (HUNT2) of the HUNT Study. All
residents in Nord-Trøndelag aged 20 years or older
were invited to attend between August 1995 and June
1997. Among a total of 93,898 invited individuals,
65,215 (69%) provided information in a self-
administered questionnaire and attended a clinical
examination that included blood sampling (15).
Among the 65,215 participants, 5,221 were excluded
because they reported a history of MI, angina pecto-
ris, or stroke, and 1,233 participants were excluded
because of missing values on relevant covariates,
leaving 58,761 participants eligible for follow-up.
Cases . The cohort members were followed up for a
ﬁrst MI, using the unique 11-digit identiﬁcation
number of Norwegian citizens as a linkage tool to
clinical information provided by the 2 hospitals that
serve Nord-Trøndelag County (Levanger and Namsos
hospitals that together make up Nord-Trøndelag
Hospital Trust). For the present study, follow-up for
MI was complete from baseline (1995 to 1997) through
2008. MI cases were diagnosed according to the Eu-
ropean Society of Cardiology/American College of
Cardiology consensus guidelines (16), and the diag-
nostic criteria included symptoms of coronary
ischemia, elevated serum levels of troponins and
cardiac enzymes, in addition to speciﬁed electrocar-
diography changes.
Contro ls . Controls were selected from the underly-
ing cohort using incidence density sampling, which is
the recommended procedure for nested case-control
studies (17). Before control selection, we had no in-
formation to indicate whether a sufﬁcient serum
volume was available, and we oversampled the con-
trols, but as a minimum, 2 controls with available
serum were selected per MI case, matched by age at
risk and sex. Use of age at risk as a time dimension
allows a very precise adjustment for age and is rec-
ommended for epidemiological studies in which the
outcome is strongly age-dependent, as is the case for
MI (18).
Among the 58,761 participants who were eligible
for inclusion at baseline, 1,700 participants were
diagnosed in hospital with a ﬁrst incident MI during a
mean follow-up of 11.3 years. A total of 1,587 of these
patients had a stored serum volume that wassufﬁcient for PCSK9 analysis. As controls, 3,959 par-
ticipants with sufﬁcient and available serum volume
were matched to the cases by age at risk and by sex.
The study was approved by the regional committee
for ethics in medical research, by the National Direc-
torate of Health, and by the Norwegian Data Inspec-
torate. Written informed consent to participate in the
study was obtained from each participant.
SERUM PCSK9 AND HIGH-SENSITIVITY C-REACTIVE
PROTEIN. Peripheral venous blood was drawn into
pyrogen-free tubes without any additives. After
clotting the blood at room temperature, the tubes
were centrifuged at 1,500g for 10 min and serum was
stored at –70C. Serum levels of PCSK9 and high-
sensitivity C-reactive protein (hsCRP) were measured
in duplicate by enzyme immune-assay with anti-
bodies obtained from R&D Systems (Minneapolis,
Minnesota). To evaluate the impact of postprandial
variation, we collected serum samples from 15 in-
dividuals sampled fasting at 8:00 AM and nonfasting
at 8:00 AM the next day. We found no effect of fasting
as on PCSK9 (7% difference; p ¼ 0.51). The intra- and
interassay coefﬁcients of variations were 4.2% and
2.5% for PCSK9 and 2.6% and 9.1% for hsCRP.
CLINICAL INFORMATION AT BASELINE. The clinical
examination in HUNT2 was conducted by trained
nurses and included standardized measurements of
blood pressure, weight, height, and waist and hip
circumference. Systolic and diastolic blood pressure
were measured with a Dinamap 845XT (Criticon/GE
Healthcare, Tampa, Florida) based on oscillometry,
and the average of the second and third measurement
was used in the analysis. Height and weight were
recorded with participants wearing light clothes
without shoes, and BMI was computed as weight
(in kilograms) divided by the squared value of height
(in meters). Information on health was collected
by means of a self-administered questionnaire.
Responses to questions related to smoking were
categorized as current, previous, or never smoking.
Creatinine was measured by the Jaffe method, and
the day-to-day coefﬁcient of variation was 3.5%.
Nonfasting serum concentrations of total cholesterol,
high-density lipoprotein cholesterol (HDL-C), and
triglycerides were measured in fresh serum samples at
Levanger Hospital using enzymatic colorimetric
methods with reagents from Boehringer Mannheim on
a Hitachi 911 Autoanalyzer (Roche Diagnostics,
Indianapolis, Indiana). The day-to-day coefﬁcients
of variation were 1.3% to 1.9%, 2.4%, and 0.7% to
1.3%, respectively. LDL-C was calculated using
Friedewald’s formula (i.e., LDL-C ¼ total cholesterol 
HDL-C  [triglycerides/2.2]). Participants with
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571triglycerides $4.52 mmol/l were excluded from the
analyses because Friedewald’s formula is invalid in
this situation. Thus, the ﬁnal study population con-
sisted of 1,488 cases and 3,819 controls.
STATISTICAL ANALYSIS. The distribution of baseline
characteristics across PCSK9 quartiles was compared
using the chi-square test for categorical variables (%)
and 1-way analysis of variance for continuous variables
(mean  SD). All covariates were tested for normality
and log transformations were performed to normalize
hsCRP and creatinine levels. Pearson correlation co-
efﬁcients were calculated to evaluate correlation be-
tween PCSK9 and the other covariates.
We used conditional logistic regression analysis to
estimate age- and sex-adjusted odds ratios (ORs, with
95% conﬁdence intervals [CIs]) of MI according to
quartile categories of PCSK9 concentrations, based on
the quartile distribution of PCSK9 among the con-
trols. Because statistical analyses were stratiﬁed on
groups of each patient and his or her matched con-
trols using conditional logistic regression analysis,
the unequal number of controls for each case did not
bias the estimates. For tests of trend of the associa-
tion across PCSK9 quartiles, we assigned each
participant the median PCSK9 level within his or her
quartile and treated these median values as a
continuous variable in the logistic models. We used a
restricted cubic spline analysis with 5 knots to assess
linearity of the association of PCSK9 with MI risk. In a
separate analysis, we also estimated the risk of MI
associated with a 1 SD higher serum PCSK9 level
assessed as a continuous variable.
In the multivariable analyses of PCSK9 levels and
MI risk, we adjusted for the following variables: BMI,
LDL-C, HDL-C, systolic blood pressure, diastolic
blood pressure, log-transformed hsCRP and creati-
nine, smoking (current, previous, or never smoking),
and diabetes mellitus (yes/no). The inclusion of po-
tential confounders to our models was based on pre-
vious knowledge concerning their relation to PCSK9
and to risk of MI (5–7,11,17). Established cardiovas-
cular risk factors such as high blood pressure, high
BMI, smoking, dyslipidemia, reduced kidney func-
tion, diabetes mellitus, and hsCRP may act as both
confounding and mediating factors for the associa-
tion of PCSK9 level with MI risk. We therefore
analyzed the data both with and without the factors
included in the analysis.
We tested for effect modiﬁcation by BMI, LDL-C,
blood pressure (high blood pressure was deﬁned
as systolic blood pressure >140 mm Hg and/or dia-
stolic blood pressure >90 mm Hg), smoking status,
diabetes mellitus, creatinine, and hsCRP. Statisticalinteraction was assessed on the multiplicative scale
by deviance tests based on comparisons of likelihoods
in nested models with and without cross-product
terms.
In a sensitivity analysis, we analyzed the ﬁrst 5
years and the rest of the follow-up separately to
assess whether the associations of PCSK9 and risk of
early MI events differed from risk of late MI events. In
another sensitivity analysis, we adjusted for the
continuous established cardiovascular risk factors
expressed as restricted cubic splines to account for
potential nonlinear associations of these risk factors
with MI risk. In another set of separate analyses, we
adjusted for untransformed hsCRP and creatinine
instead of the log-transformed variables. Because
blood sampling was nonfasting, blood lipid values,
especially triglyceride levels, could be inﬂuenced by
recent food intake. In a sensitivity analysis, we
therefore adjusted for time since last meal.
All statistical analyses were conducted in STATA,
version 12.2, for Windows (StataCorp LP, College
Station, Texas).
RESULTS
BASELINE CHARACTERISTICS. At baseline, mean
age was 66.2  12.8 years, and 62.9% of the partici-
pants were men. PCSK9 concentrations were slightly
skewed to the right, as shown in Supplemental
Figure 1. Among MI cases, the median PCSK9 con-
centration was 128 ng/ml (interquartile range: 76 to
182 ng/ml) compared to 121 ng/ml (interquartile
range: 69 to 174 ng/ml) among controls (p < 0.001).
The median value was higher in women than in men;
136 ng/ml versus 116 ng/ml (p < 0.001).
The baseline characteristics of participants within
each PCSK9 quartile are shown in Table 1. Participants
in the higher quartiles of PCSK9 were more likely to
be women; current smokers; have higher levels of
creatinine, hsCRP, and BMI; and generally a more
unfavorable serum lipid proﬁle compared with those
in the lower quartiles. However, levels of HDL-C were
higher among participants in the higher quartiles of
PCSK9. Assessed as a continuous variable, serum
PCSK9 concentrations correlated positively with
LDL-C (r ¼ 0.21; p < 0.001), total cholesterol (r ¼ 0.27;
p < 0.001), triglycerides (r ¼ 0.12; p < 0.001), BMI
(r ¼ 0.12; p < 0.001), and log-transformed (hsCRP)
(r ¼ 0.18; p < 0.001).
PCSK9 IN SERUM AND RISK OF MI. Table 2 presents
the age- and sex-adjusted and several multivariable-
adjusted ORs for MI according to PSCK9 quartiles
and per SD higher serum PCSK9 level. Compared with
TABLE 1 Baseline Characteristics by Quartiles of PCSK9: The HUNT Study
Total
(N ¼ 5,307)
Quartile 1
(n ¼ 1,264)
Quartile 2
(n ¼ 1,281)
Quartile 3
(n ¼ 1,363)
Quartile 4
(n ¼ 1,399) p Value
PCSK9, ng/ml <98 98 –<121 121 –<151 >151
PCSK9, ng/ml 123 (53) 84 (22) 110 (11) 134 (15) 177 (39)
Age, yrs 66.2  12.8 65.2  13.3 66.2  12.7 67.3  12.4 66.0  12.6 0.08
Male 3,340 (62.9) 1,004 (79.4) 859 (67.1) 786 (57.7) 691 (49.4) <0.001
Current smoking 1,466 (27.6) 357 (28.2) 329 (25.7) 373 (27.4) 407 (29.1) 0.001
Diabetes mellitus 280 (5.3) 82 (6.5) 70 (5.5) 61 (4.5) 67 (4.8) 0.10
Systolic blood pressure, mm Hg 150.7  23.8 148.1  23.2 148.9  24.2 152.1  23.1 153.2  24.3 0.13
Diastolic blood pressure, mm Hg 85.3  12.1 84.7  12.1 84.5  12.3 86.2  12.0 85.8  11.8 0.45
Total cholesterol, mmol/l 6.4  1.2 5.9  1.0 6.2  1.1 6.5  1.2 6.8  1.3 <0.001
LDL-C, mmol/l 4.2  1.1 3.8  0.9 4.1  1.0 4.3  1.1 4.5  1.2 <0.001
Triglycerides, mmol/l 1.9  0.8 1.7  0.8 1.8  0.8 1.9  0.8 2.0  0.9 0.03
HDL-C, mmol/l 1.35  0.39 1.33  0.3 1.32  0.36 1.37  0.39 1.38  0.40 0.001
BMI, kg/m2 26.9  3.9 26.3  3.5 26.6  3.7 27.1  4.0 27.5  4.2 <0.001
Creatinine, mmol/l 90.0  18.0 92.0  18.0 91.0  19.0 90.0  17.0 88.0  18.0 <0.001
hsCRP median, mg/l 2.1 (2.4) 1.7 (2.0) 2.0 (2.2) 2.2 (2.6) 2.5 (2.6) <0.001
Values are range, median (interquartile range), mean  SD, or n (%).
BMI ¼ body mass index; HDL-C ¼ high-density lipoprotein cholesterol; hsCRP ¼ high-sensitivity C-reactive protein; HUNT ¼ the Nord-Trøndelag Health Study;
IQR ¼ interquartile range; LDL-C ¼ low-density lipoprotein cholesterol; PCSK9 ¼ proprotein convertase subtilisin-kexin type 9.
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572participants in the lowest quartile, MI risk was 47%
higher among participants in the highest quartile,
after adjustment for age and sex. Across quartiles, the
ORs from lowest (reference) to highest serum PCSK9
quartile were 1.16 (95% CI: 0.96 to 1.40), 1.35 (95% CI:
1.13 to 1.63), and 1.47 (95% CI: 1.23 to 1.77), (p for
linear trend <0.001). However, after adjustment for
established cardiovascular risk factors, including
serum lipids, BMI, diabetes, smoking, blood pressure,
creatinine, and hsCRP (Table 2, model 4), the associ-
ation of PSCK9 with MI risk was strongly attenuated,
and there was no convincing trend across quartiles
(p for linear trend ¼ 0.53). Among factors included in
the multivariable analysis, LDL-C appeared to be the
single most important factor to attenuate theTABLE 2 Association of PCSK9 With Risk of MI: The HUNT Study
PCSK9 Quartiles (ng/ml)
Q1
(<98)
Q2
(98<121)
Q3
(121<151)
Cases 298 (23.6) 336 (26.2) 407 (29.9) 4
Controls 966 (76.4) 945 (73.8) 956 (70.1) 9
Model 1‡ 1.00 (ref) 1.16 (0.96–1.40) 1.35 (1.13–1.63) 1.47
Model 2§ 1.00 (ref) 1.08 (0.89–1.30) 1.18 (0.97–1.42) 1.17
Model 3k 1.00 (ref) 1.04 (0.86–1.26) 1.12 (0.92–1.35) 1.10
Model 4¶ 1.00 (ref) 1.06 (0.87–1.29) 1.10 (0.90–1.34) 1.07
Values are n (%) or odds ratio (95% conﬁdence interval). *For tests of trend of the assoc
and treated these median values as a continuous variable in the logistic models. †1 SD ¼
age, sex, LDL-C, HDL-C, and triglycerides. ¶Adjusted for age, sex, diabetes mellitus, L
HDL-C, log-transformed creatinine, and log-transformed C-reactive protein.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviation as in Table 1.association of PCSK9 with MI risk, followed by serum
triglycerides and HDL (Table 2, models 2 and 3).
Using PCSK9 as a continuous variable, the OR of MI
per SD (47 ng/ml) higher serum PCSK9 at baseline was
1.13 (95% CI: 1.07 to 1.20) in the age- and sex-adjusted
analysis (Table 2). We also expressed PCSK9 concen-
trations as restricted cubic splines, and found that the
age- and sex-adjusted association of PCSK9 with MI
risk displayed a nonlinear shape. Thus, there was a
gradual increase in MI risk starting at approximately
100 to 175 ng/ml of PCSK9, followed by a leveling
off (Figure 1A). After adjustment for established car-
diovascular risk factors, the cubic spline analysis
suggested that PCSK9 concentrations were not asso-
ciated with increased MI risk (Figure 1B).p for
Linear Trend*
Per 1 SD†
Higher PCSK9
Q4
(>151)
Linear
Trend*
47 (32.0)
52 (68.0)
(1.23–1.77) 1.04 (1.02–1.06) <0.001 1.13 (1.07–1.20)
(0.97–1.42) 1.02 (1.00–1.04) 0.09 1.04 (0.97–1.10)
(0.90–1.34) 1.01 (0.99–1.03) 0.32 1.03 (0.96–1.09)
(0.88–1.32) 1.01 (0.99–1.03) 0.53 1.02 (0.95–1.09)
iation, we assigned each participant the median PCSK9 level within his or her quartile,
47 ng/ml. ‡Adjusted for age and sex. §Adjusted for age, sex, and LDL-C. kAdjusted for
DL-C, BMI, smoking, systolic blood pressure, diastolic blood pressure, triglycerides,
FIGURE 1 Sex- and Age- and Multi-Adjusted* Association Between Serum
PCSK9 Concentrations (Expressed as a Restricted Cubic Spline) and
Risk of Incident MI (ORs; 95% CI)
(A) Sex- and age-adjusted; (B) multi-adjusted. *Adjusted for age, sex, dia-
betes mellitus, LDL-C, BMI, smoking, systolic blood pressure, diastolic blood
pressure, triglycerides, HDL-C, log-transformed creatinine, and log-
transformed C-reactive protein. †ORs with 95% CIs are displayed at the 2.5, 5,
10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 and 97.5
percentiles of PCSK9, based on the quantile distribution among controls and
using the 5th percentile as the reference level. BMI ¼ body mass index;
CI ¼ conﬁdence interval; HDL-C ¼ high-density lipoprotein cholesterol;
LDL-C ¼ low-density lipoprotein cholesterol; MI ¼ myocardial infarction;
OR ¼ odds ratio; PCSK9 ¼ proprotein convertase subtilisin-kexin type 9.
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573We found no statistical evidence for any effect
modiﬁcation of PCSK9 by LDL-C (p for interaction ¼
0.51), and no evidence that the association of serum
PCSK9 with MI risk could be modiﬁed by other car-
diovascular risk factors, including BMI, current
smoking, hypertension, diabetes mellitus, creatinine,
or hsCRP (all p for interaction >0.05).
SENSITIVITY ANALYSIS. In sensitivity analyses
(Supplemental Tables 1A and 1B), the estimated asso-
ciations did not differ for MI events (N ¼ 559) that
occurred during the ﬁrst 5 years of follow-up compared
with later MI events (N ¼ 929) (p for interaction with
early vs. late follow-up ¼ 0.96). Using restricted cubic
splines of the continuous established cardiovascular
risk factors in the multivariable analysis showed
results that were similar to the main ﬁndings
(Supplemental Table 2). Adjustment for untrans-
formed hsCRP and creatinine instead of the log-
transformed variables showed similar results (data
not shown). Adjustment for time between last meal
and the venipuncture had virtually no effect on the
results (data not shown).
DISCUSSION
In this large prospective population study of in-
dividuals free of clinical CVD at baseline, serum levels
of PCSK9 were positively but modestly associated
with risk of MI in age- and sex-adjusted analysis.
However, after adjustment for established CVD risk
factors, the strength of the association was strongly
attenuated. Most of the attenuation could be attrib-
uted to LDL-C followed by serum triglycerides and
HDL-C. Thus, our results suggest that the association
of PCSK9 may reﬂect an effect involving the meta-
bolism of lipids rather than being an independent risk
factor for MI. Moreover, our results are consistent
with the biological understanding of PCSK9 and of its
effect on atherosclerosis being mainly mediated by
changes in LDL-receptor function.
The association of PCSK9 with CVD risk has not
been well-studied in population studies. A few rela-
tively small studies from the general population have
prospectively investigated circulating PCSK9 levels
and risk of CVD, and the results have been conﬂicting
(11–13). In a nested case-control study from the
Nurses’ Health Study, including 358 women in each
group, Ridker et al. (12) reported that PCSK9 levels
were not associated with increased risk of CVD events
during 17 years of follow-up. Similarly, Zhu et al. (13)
found no evidence for a strong association between
log-transformed serum PCSK9 and CVD events in
1,527 middle-aged men over a 7-year follow-up after
adjustment for established cardiovascular risk factors(hazard ratio: 1.16 [95% CI: 0.93 to 1.44]). Moreover,
PCSK9 was not associated with measures of vascular
structure and function, such as carotid intima media
thickness or ﬂow-mediated dilatation. However,
direct comparison of these studies is complicated by
sex differences because the association between
LDL-C and PCSK9 may be sex-dependent (19). Results
of a recent study suggested that circulating PCSK9
may be elevated either immediately before or at the
time of MI; therefore, time from baseline measure-
ment until event may be too long to capture any
effect of PCSK9 (20). We could not address that pos-
sibility, but in a sensitivity analysis, we explored
whether PCSK9 might reﬂect preclinical or underlying
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574disease by excluding the ﬁrst 5 years of follow-up, but
the results remained essentially unchanged.
However, contradictory to these previous ﬁndings,
the recent prospective study of Leander et al. (11)
reported a positive dose-dependent association be-
tween PCSK9 and risk of CVD events. During 15 years
of follow-up, 491 of 4,232 men and women 60 years
of age at baseline had an incident CVD event. In that
study, the strength of the crude association of PCSK9
with CVD risk was roughly comparable to the
strength of the age- and sex-adjusted result in the
present study. Whereas adjustment for LDL-C
attenuated the association in our study, serum
PCSK9 was positively associated with CVD risk also
after extensive covariate adjustment, including
LDL-C, in the study by Leander et al. (11) Thus, the
adjusted hazard ratios across PSCK9 quartiles were
1.15 (95% CI: 0.88 to 1.50), 1.24 (95% CI: 0.94 to 1.63),
and 1.48 (95% CI: 1.12 to 1.95), p for trend 0.0063.
Although our outcomes were based on incident
hospitalizations because of MI, the study by Leander
et al. evaluated a composite endpoint of ischemic
CVD events including both fatal and nonfatal MI and
stroke, as well as chronic ischemic heart disease and
sudden cardiac death. Moreover, because of a limited
number of CVD events, the authors did not report
subgroup analyses for MI and stroke; thus, it is un-
known whether the stronger association with CVD
events in their study could partly be driven by cause-
speciﬁc events. Although the association between
lipids and coronary heart disease is ﬁrmly estab-
lished, the association between lipids and ischemic
stroke is not equally robust (21). The stronger asso-
ciation observed in the study of Leander et al. (11)
could therefore reﬂect lipid independent car-
diometabolic (e.g., inﬂammation, apoptosis) effects
of PCSK9 with a stronger impact on non-MI CVD (22).
Strengths of the present study include the rela-
tively large sample size and the selection of a mini-
mum of 2 controls for each of the 1,488 MI cases,
preserving two-thirds of the statistical power that
would be achieved by using the whole cohort. Other
strengths are the prospective recording of incident
MIs, and that biases resulting from recall or self-
selection are avoided. Also, the incidence density
sampling secures unbiased OR estimates of the
incidence rate ratios that would be calculated in the
underlying cohort. Thus, this type of nested case-
control study is prospective in design and consid-
ered to be equivalent to cohort studies in terms of
validity (17). Moreover, all MIs were veriﬁed in the
hospitals, and the speciﬁcity of the diagnosis is likely
to be very high (17). It is a limitation of the study that
we cannot exclude that serum concentrations ofPCSK9 and hsCRP may have changed during the
approximately 15 years of storage before analysis.
However, storage time did not differ between cases
and controls, and it seems unlikely that any changes
during storage time would systematically differ be-
tween cases and controls. Furthermore, we cannot
exclude the possibility of confounding by unmea-
sured factors behind our observations, including lip-
oprotein(a), which was not measured in the HUNT
study. However, to inﬂuence our results substan-
tially, any remaining confounder would need to be
strongly associated with both PCSK9 and MI and
generally be unrelated to the other factors we
included in our multivariable models. Moreover, we
had no information on the use of statins, and statins
may increase PCSK9 levels (23) and are also beneﬁcial
for the prevention of MI; thus, the use of statins may
potentially confound the association of PCSK9 with
MI risk. However, the use of statins as primary car-
diovascular prevention was uncommon in Norway at
the time of the HUNT survey in 1995 to 1997 (24), and
in our study, we only included individuals with no
history of CVD (MI, angina, or stroke). Thus, con-
founding from use of statins should be limited in our
study. PCSK9 has been reported to display consider-
able diurnal variation (25,26). In the HUNT study, all
blood samples were drawn between 8:00 AM and 4 PM,
but we had no exact information on time during the
day the blood sampling was done. However, adjust-
ment for time between last meal and blood sampling
had no effect on the estimated results. Nevertheless,
a standardized sampling at 1 time would have been
the best, and this represent a limitation in our study.
CONCLUSIONS
High levels of PCSK9 were positively but modestly
associated with risk of MI in age- and sex-adjusted
analysis, but the association was largely attenuated
after adjustment for LDL-C. Our results are consistent
with the biological understanding of PCSK9 and of its
effect on atherosclerosis being mainly mediated by
changes in LDL-receptor function. Whereas PCSK9
has emerged as a novel target for preventing and
limiting the development of coronary artery disease,
our ﬁndings suggest that blood levels of PCSK9 do not
contribute additional useful information in cardio-
vascular risk assessment beyond the information
provided by lipid measurements.
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